Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats

International Journal of Tissue Reactions

Volumn 27, Issue 4, 2005, Pages 203-211

  Noa, M ^a   Arruzazabala, M L ^a   Carbajal, D ^a   Más, Rosa ^a   Molina, V ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

D 004; LIPID; PLANT EXTRACT; PROSEREN; ROYSTONEA REGIA EXTRACT; SABAL EXTRACT; SOYBEAN OIL; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; FRUIT; HISTOPATHOLOGY; MALE; MICROSCOPY; NONHUMAN; PROSTATE HYPERTROPHY; RAT; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANIMALS; ARECACEAE; DOSE-RESPONSE RELATIONSHIP, DRUG; INTUBATION, GASTROINTESTINAL; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

ANIMALIA; ARECACEAE; GLYCINE MAX; RODENTIA; ROYSTONEA; ROYSTONEA REGIA; SABAL; SERENOA REPENS;

EID: 30344462975     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Irant J., Brown C.T., van der Meulen J., Eberton M. A review of guidelines on benign prostate hyperplasia and lower urinary tract symptoms. BJU Int, 92, 937, 2003.
2. Oesterling J.E. Benign prostatic hyperplasia: Medical and minimal invasive treatment options. N. Engl. J. Med., 332, 99, 1995.
3. Barry M.J., Rochrborn C.G. Benign prostatic hyperplasia. BMJ, 324, 775, 2001.
4. Bhargava S., Canda A.E., Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation. Recent advances. Curr Opin. Urol., 14, 1, 2004.
5. Coffey D.S., Walsh P.C. Clinical and experimental studies of benign prostatic hyperplasia. Urol. Clin. North Am., 17, 461, 1990.
6. Austin O., Ricer R.E. Prostate cancer screening. An appraisal of the PSA test. Fam. Pract. Recert., 18, 81, 1996.
7. Carson C., Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(Suppl. 1), 2, 2003.
8. Lam J.S., Romas N.A., Lowe F.C. Long term treatment with finasteride in men with symptomatic benign prostatic hyperplasia. 10 year follow up. Urology, 61, 354, 2003.
9. Sandhu J.S., Te A.E. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr. Urol. Rep., 5, 274, 2004.
10. Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A, 41, 412, 2002.
11. Roehrborn C.G., Schwinn D.A. Alpha-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J. Urol., 171, 1029, 2004.
12. Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. An update. Urology, 53, 671, 1999.
13. Gerber G.S. Saw palmetto for the treatment of men with lower urinary tract symptoms. J. Urol., 163, 1408, 2000.
14. Marks L.S., Tyler V.E. Saw palmetto extract: Newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology, 53, 457, 1999.
15. Carraro J.C., Raynaud J.P., Koch G. et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate, 29, 231, 1996.
16. Rhodes L., Primka R.L., Berman C. et al. Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts on in vitro and in vivo 5 α-reductase inhibition. Prostate, 22, 43, 1993.
17. Andro M.C., Riffaud J.P. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience. Curr. Ther. Res. Clin. Exp., 56, 796, 1995.
18. Bombardelli E., Morazzoni P., Small J.K. Serenoa repens (Bartram). Fitoterapia, 68, 99, 1997.
19. Carbajal D., Molina V., Más R., Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exptl. Res. (in press).
20. Carbajal D., Arruzazabala M.L., Más R. et al. Effects of D-004, a lipid extract from Cuban Royal Palm fruit, on inhibiting prostatic hyperplasia induced with testosterone or fihydrotestosterone in a rat model: A randomized, controlled study. Curr. Ther. Res., 65, 505, 2004.
21. Pandita R.K., Persson K., Hedlund P., Andersson K.E. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate, 35, 102, 1998.
22. Scolnik M.D., Servadio C., Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J. Androl., 15, 287, 1994.
23. Mahapokai W., Van Sluijs F.J., Schalken J.A. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis., 3, 28, 2000.
24. Paubert-Braquet M., Richardson F.O., Servent-Saez N. et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol. Res., 34, 171, 1996.
25. Marks L.S., Partin A., Dorey F. et al. Long term effects of finasteride on prostate tissue composition. Urology, 53, 574, 1999.
26. Hayami S., Ushiyama T., Kurita Y., Kagayama S., Suzuki K., Fujita K. The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. Prostate, 53, 168, 2002.
27. Buck A.C. Phytotherapy for the prostate. Brit. J. Urol., 78, 325, 1996.
28. Marks E. Effects of Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol., 163, 1451, 2000.
29. Veltri R.W., Marks L.S., Miller M.C., Bales W.D., Fan J., Macairan M.L. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH. Evidence for a possible mechanism. Urology, 60, 617, 2002.